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ABSTRACT
Objectives: The aim of this study was to investigate the economic conse-
quences of nucleoside analog therapy for hepatitis B treatment in China.
Methods: A cost-utility analysis of treatments for HBeAg-positive and
HBeAg-negative chronic hepatitis B (CHB) was conducted using a Markov
model, in which patients’ yearly transitions between different health states
were tracked. Patients were tracked as they moved between the following
health states: CHB, HBeAg seroconversion (HBeAg-positive CHB patients
can have this special health state), virologic resistance, virologic response,
compensated cirrhosis, decompensated cirrhosis, hepatocellular carci-
noma, liver transplantation, and death. The transition parameters were
derived either from systematic reviews of the literature or from previous
economic studies. Cost and utility data came from studies based on a
Chinese CHB cohort. One-way sensitivity analyses as well as second-order
Monte Carlo and probabilistic sensitivity analyses were performed.
Results: The entecavir strategy yielded the most quality-adjusted life years
(QALYs) for both HBeAg-positive and HBeAg-negative patients when
compared with the “no treatment,” the lamivudine, the adefovir, and the
telbivudine strategies. The risks of complications and mortality also
decreased. In the economic analysis, the “no treatment” strategy was the
least effective, whereas the entecavir strategy was both the least expensive
and the most cost-effective option, followed by telbivudine and lamivu-
dine. The probabilistic sensitivity analysis showed that the entecavir strat-
egy would result in improved cost-effectiveness in >90% of cases at a
threshold of $20,000 per QALY. In a one-way sensitivity analysis, the most
inﬂuential parameters impacting the model’s robustness were the utilities
of the CHB and virologic response health states.
Conclusions: In China, when treating both HBeAg-positive and HBeAg-
negative CHB populations, entecavir is the most cost-effective option
when compared with lamivudine, adefovir, and telbivudine.
Keywords: China, chronic hepatitis B, cost-effectiveness, nucleoside
analogs.
Introduction
Chronic hepatitis B (CHB) infection is a global public health
problem that affects 350 to 400 million people worldwide and is
particularly prevalent in China. Epidemiological surveys indicate
that approximately 112 million Chinese people are chronically
infected with the hepatitis B virus (HBV) [1,2]. Persistent HBV
infection is a signiﬁcant cause of cirrhosis, hepatocellular carci-
noma (HCC), and liver failure. These advanced complications of
CHB increase the risk of morbidity and mortality and result in
higher health-care costs [1].
The ultimate goal of CHB treatment is to completely eradi-
cate HBV, but currently available therapies rarely achieve this
ideal goal. Short of HBV eradication, the primary aim of antiviral
treatment of CHB is to prevent or reduce the disease progression
risk associated with cirrhosis and HCC. Serum HBV DNA is a
marker of active infection in CHB, and several studies have
shown that serum HBV DNA levels are a strong predictor of the
development of cirrhosis and HCC, independent of HBeAg status
and alanine aminotransferase (ALT) levels [3]. These important
ﬁndings indicate that effective and prolonged viral suppression
may protect against cirrhosis and the development of HCC. In
addition to lamivudine, there are currently three oral nucleoside
analogs available in China to treat patients with CHB. These
include adefovir dipivoxil, telbivudine, and entecavir. Several
large clinical trials have shown that these newer agents have
stronger antiviral activity when compared with either a placebo
or lamivudine [4]. The latest guidelines by the American Asso-
ciation for the Study of Liver Diseases, the European Association
for the Study of the Liver (EASL), and the Asian Paciﬁc Associa-
tion for the Study of the Liver recommend pegylated interferon,
entecavir or tenofovir as ﬁrst-line treatment for patients with
CHB [3,5,6]. These recommendations, however, do not take into
consideration the long-term therapy costs. Several recently pub-
lished studies compared the cost-effectiveness of different oral
nucleoside analog strategies for the treatment of patients with
CHB [7–12]. Most of these studies, however, came from devel-
oped countries. In China, which has the largest hepatitis B
population of any developing country, there are still very few
long-term economic analyses of these oral antiviral medicines.
Although current guidelines indicate that interferon treatment
might be an option for ﬁrst-line treatment, it was not included in
the current economic analysis because the pharmacological
mechanisms of nucleoside analogs and interferon are different.
The former directly inhibit the replication of HBV, whereas the
latter eradicates the virus by enhancing the host’s immunity; a
comparison between different types of medicines may not be fair
[13,14]. The object of the present study is to evaluate the relative
clinical beneﬁts and cost-effectiveness of long-term oral antiviral
therapies in a cohort of Chinese patients with CHB.
Methods
The Analytic Model
Markov models were used to simulate lifetime clinical and
economic outcomes associated with CHB and its treatment.
The cost-effective analytic model of HBeAg-positive CHB was
composed of nine mutually exclusive health states: CHB,
HBeAg seroconversion, virologic resistance, virologic response,
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compensated cirrhosis, decompensated cirrhosis, HCC, liver
transplantation, and death (Fig. 1). Except in the case of HBeAg
seroconversion, the health states of HBeAg-negative CHB
patients were similar to those of the HBeAg-positive patients.
The cycle length in the Markov model was 1 year, and patients
began in the CHB state. During each 1-year cycle, individual
CHB patients either remained in their assigned health state
(recursive arrow) or progressed to a new health state (straight
arrow).
Recently published studies have shown that the HBV DNA
level is an important and independent risk factor for disease
progression in CHB [3]. The results also indicated that HBV
DNA levels might be an ideal surrogate marker for antiviral
therapies. For these reasons, we used the states of “virologic
response” and “virologic resistance” in the current analytic
model. When a CHB patient is categorized in the “virologic
response” health state, the risk of progressing to HCC or cirrho-
sis decreases. When a CHB patient is in the “virologic response”
health state, the risk of progressing to HCC or cirrhosis
decreases. When a CHB patient is in the “virologic resistance”
health state, however, the consequent increase in serum HBV
DNA level raises the risk of HCC and cirrhosis. To the best of our
knowledge, we think that the health states of “virologic
response” and “virologic resistance” are pivotal because they
determine the clinical outcomes of CHB treatment [3]. In addi-
tion, similar to Kanwal et al. we classiﬁed the states of CHB,
virologic response, and CHB with resistance as precirrhosis
stages; depending on the HBV DNA level, however, the former
two states could progress to compensated cirrhosis or HCC. We
did not include the health states of virologic relapse or treated
chronic HBV because we assumed that the HBV DNA level of
these two states is likely equivalent to that of CHB, with a
similarly increased risk of complications. We created a special
HBeAg seroconversion state for the HBeAg-positive cohort
because a patient who has achieved HBeAg seroconversion might
discontinue therapy and would differ from a patient who only
achieves virologic response.
A hypothetical Chinese cohort of 30-year-old HBeAg-positive
or HBeAg-negative patients with CHB was entered into the
model [15]. Hypothetical patients were nucleoside-naïve, HBV
DNA-positive and noncirrhotic, and had elevated ALT levels.
They received one of the following ﬁve competing strategies to
manage chronic HBV infection [4,6,16]: no pharmacologic treat-
ment (“no treatment” strategy), lamivudine monotherapy
(100 mg/day) with added adefovir (10 mg/day) upon develop-
ment of lamivudine resistance (“lamivudine” strategy), adefovir
monotherapy (10 mg/day) with added entecavir (0.5 mg/day)
upon development of adefovir resistance (“adefovir” strategy),
telbivudine monotherapy (600 mg/day) with added adefovir
(10 mg/day) upon development of telbivudine resistance (“telbi-
vudine” strategy), or entecavir monotherapy (0.5 mg/day) with
added adefovir (10 mg/day) upon development of entecavir resis-
tance (“entecavir” strategy). In HBeAg-positive patients, those
who achieved HBeAg seroconversion would discontinue therapy
after an additional 12 months. The HBeAg-negative patients and
HBeAg-positive patients without a sustained virological response
off-treatment and without HBeAg seroconversion would receive
unlimited treatment with nucleoside analogs.
Both cost and health outcomes in the model were discounted
at 3% annually to allow for current values.
Clinical Data
Transition probabilities and proportions (Table 1) for Chinese
CHB patients were derived from a systematic review of the
literature and when possible, from previous economic studies.
The annual transition probabilities from CHB to advanced
disease complications (compensated cirrhosis and HCC)
depended on the serum HBV DNA level. The Risk Evaluation of
Viral Load Elevation and Associated Liver Disease/Cancer-
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Figure 1 Markov diagram of health states and possible transitions between them during each 1-year cycle. During each 1-year cycle, individual chronic hepatitis B
(CHB) patients either remained in their assigned health state (recursive arrow) or progressed to a new health state (straight arrow).Transition rates between health
states were derived either from systematic reviews of the literature or from previous studies.
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Hepatitis B Virus (REVEAL-HBV) study found that the HBV
DNA across a biologic gradient very strongly predicts increased
risk of disease progression and remains a strong predictor of risk
after accounting for other important factors [3]. Furthermore,
other studies have indicated that decreased HBV DNA levels
(HBV DNA <300–400 copies/ml) due to nucleoside analogs
could result in biochemical remission, histological improvement,
and protection from HBV-related complications and were asso-
ciated with a lower risk of HBV drug resistance [13].
Efﬁcacy and resistance data (Table 2) for lamivudine, adefovir,
entecavir, and telbivudine came from multicenter, double-blind,
randomized controlled trials. CHB patients adhering to the “no
treatment” strategy progressed according to the natural history of
CHB and followed the corresponding annual rates of progression.
Cost and Quality-of-Life Data
We performed our analysis from the perspective of the Chinese
social security program, incorporating direct health-care costs for
medication, physician visits, laboratory tests, examinations, and
complications of chronic liver disease (Table 3). Indirect costs and
lost productivity were not included. The costs were obtained from
previous studies [2,17]. The costs were then converted to 2009 US
dollars (US $1 = CNY 6.83). All drug costs were based on current
ofﬁcial prices approved by the Shanghai Municipal Bureau of
Pricing. The cost of liver transplantation was obtained from a
published Chinese academic dissertation [18].
The health state utilities for Chinese CHB patients (Table 3)
were obtained primarily from a multinational study [19]. The
utility for patients who achieved HBeAg seroconversion was
assumed to be equivalent to that of uninfected respondents.
Analysis
Each rate, cost, and utility was put into the model with its
appropriate distribution: normal distributions were adopted for
costs, whereas b distributions were adopted for probabilities,
proportions, and utilities [8]. A probabilistic sensitivity analysis
(PSA) based on a second-order Monte Carlo simulation (1000
simulations) was conducted [20], and cost-effectiveness plane
acceptability curves were plotted [21]. The base-case analysis
was run on a lifetime horizon. Finally, to evaluate the impact of
parameter uncertainty on the robustness of the ﬁndings, we
conducted one-way sensitivity analyses for all the variables over
the ranges shown in Tables 1–3. The results were expressed as
tornado charts.
Results
Base-Case Treatment Analyses
Our model calculated the lifetime cumulative costs, quality-
adjusted life years (QALYs), incremental QALYs, incremental
Table 1 Base-case probability estimates* for the natural history of chronic hepatitis B
Initial state State reached
Model input (range)
ReferenceHBeAg(+) HBeAg(-)
Chronic hepatitis B Spontaneous virologic response 6.9 (2–23) 1.6 (1–11) [12]
Compensated cirrhosis§ 2 (1–3) 2 (1–3) [3]
Hepatocellular carcinoma§ 1.0 (0.3–1.5) 1.0 (0.3–1.5) [3]
Virologic response Compensated cirrhosis§ 0.4 (0.2–0.6) 0.4 (0.2–0.6) [3]
Hepatocellular carcinoma§ 0.2 (0.1–0.4) 0.2 (0.1–0.4) [3]
Durability† 80 (20–100) 80 (20–100) [16]
Compensated cirrhosis Decompensated cirrhosis 7.3 (3.5–10) 7.3 (3.5–10) [12]
Hepatocellular carcinoma 3.4 (1–10) 3.4 (1–10) [12]
Death 4.9 (2–14) 4.9 (2–14) [12]
Decompensated cirrhosis Hepatocellular carcinoma 3.4 (1–10) 3.4 (1–10) [12]
Liver transplantation‡§ 5 (1–10) 5 (1–10) expert panel
Death§ 14.4 (10–20) 14.4 (10–20) [17,18]
Hepatocellular carcinoma Liver transplantation‡§ 5 (1–10) 5 (1–10) expert panel
Death 23.3 (20–30) 23.3 (20–30) [9,10]
Liver transplantation Death 7 (2–12) 7 (2–12) [12]
*All values are percentages, unless otherwise indicated.
†The durability of spontaneous virologic response was assumed to be equal to the durability for HBeAg-positive patients who seroconvert on treatment and prolong treatment for an additional
12 months.
‡The annual probability in China was estimated by an expert panel.
§These data were derived from a cohort of Chinese CHB patients.
HBeAg, hepatitis B e antigen.
Table 2 Base-case annual treatment-related probability estimates*
Drug/strategy Lamivudine
Model input (range)
ReferencesAdefovir Telbivudine Entecavir
HBeAg(+)
Virologic response 39 (30–50) 21 (15–28) 60 (53–68) 67 (55–75) [13,16]
HBeAg seroconversion 22 (15–30) 12 (5–15) 23 (15–30) 21 (15–30) [13,16]
Durability† 80 (20–100) 80 (20–100) 80 (20–100) 80 (20–100) [13,16]
Resistance 14 (10–20) 6 (3–8) 11 (5–15) 0.2 (0.1–0.3) [16,17]
HBeAg(-)
Virologic response 72 (60–80) 51 (40–60) 88 (85–95) 90 (85–95) [13,16]
Resistance 14 (10–20) 6 (3–8) 11 (5–15) 0.2 (0.1–0.3) [16,17]
*All values are percentages, unless otherwise indicated. HBeAg: hepatitis B e antigen.
†The durability of HBeAg seroconversion is assumed to be similar with different oral nucleoside analogs.
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costs, incremental cost-effectiveness ratios (ICERs), and inci-
dences of cirrhosis, HCC and death for the ﬁve treatment strat-
egies (Table 4).
In the HBeAg-positive cohort, the entecavir strategy led to a
gain of 11.8 QALYs, with incidences of cirrhosis, HCC, and
death of 23.8%, 14.8%, and 23.0%, respectively. Compared
with other treatment options, entecavir achieved the best health
outcomes. In this cohort, the least expensive strategy was no
treatment. The economic outcomes of alternative strategies are
presented in Figure 2a. The “no treatment” strategy was the
baseline comparator; adefovir was less cost-effective than lami-
vudine (with fewer health beneﬁts and higher costs) and lamivu-
dine and telbivudine showed even fewer health beneﬁts and less
cost-effectiveness. The ICER of entecavir versus no treatment
was $12,700 per additional QALY gained.
In the HBeAg-negative cohort, the entecavir strategy also
achieved the highest health beneﬁts compared with the other
options (Table 4). The economic analyses showed that entecavir
was the most cost-effective strategy (“no treatment” was the
baseline comparator) (Fig. 2b). The ICER of entecavir versus no
treatment was $9300 per additional QALY gained.
Uncertainty Analyses
The one-way sensitivity analyses showed that some model
parameters have a substantial impact on the results. The 10 most
inﬂuential parameters in both the HBeAg-positive and the
HBeAg-negative cohorts are presented in the tornado graphs
(Fig 3a,b). For the HBeAg-positive cohort, the most inﬂuential
parameters were the utilities of the CHB and the virologic
response health states, the virologic response rates on entecavir,
and the HBeAg seroconversion rates on entecavir. The CHB state
utility had the greatest inﬂuence on the net health beneﬁt. Param-
eters such as the probability of transition from the virologic
response state to HCC, the probability of transition from the
CHB state to HCC, and the probability of sustainability of the
virologic response were also inﬂuential. Nevertheless, other
parameters, including drug costs and other disease utilities, had
little impact on the robustness of the model. For the HBeAg-
negative cohort, the most inﬂuential parameters were the viro-
logic response state utility, the CHB state utility, and the virologic
response rates on entecavir. The virologic response state utility
had the greatest inﬂuence on net health beneﬁt. Parameters such
as the probability of transition from the virologic response state
to HCC and compensated cirrhosis, the annual cost of entecavir,
and the virologic response state were also inﬂuential. Other
parameters had little impact on the robustness of the model.
The results of the probabilistic sensitivity analysis indicated
that for both HBeAg-positive and HBeAg-negative patients, the
no treatment strategy was the most competitive option when
cost-effectiveness thresholds were below approximately $11,000
per QALY (Fig 4a,b). When the threshold was set at $20,000 per
Table 3 Base-case annual cost estimates ($, 2009 values) and utilities
Average disease costs (per patient/year) Model input (range) References
Drug costs
Lamivudine 856 (800–900) [20]
Adefovir 1,068 (1,000–1,100) [20]
Telbivudine 1,282 (1,250–1,350) [20]
Entecavir 2,137 (2,100–2,200) [20]
Health state costs
Chronic hepatitis B (CHB) 132 (100–200) [17]
Virologic response 132 (100–200) Assumed similar to CHB
HBeAg seroconversion 132 (120–200) Assumed similar to CHB
Compensated cirrhosis 224 (200–300) [17]
Decompensated cirrhosis 2,020 (1,500–2,500) [17]
Hepatocellular carcinoma 5,629 (5,000–10,000) [17]
Liver transplantation 43,923 (43,000–50,000) [18]
Postliver transplantation 7,320 (7,000–9,000) [18]
Health state utilities (quality of life)
Chronic hepatitis B 0.52 (0.5–0.7) [19]
Virologic response 0.71 (0.65–0.8) [19]
HBeAg seroconversion 0.71 (0.6–0.8) Assumed similar to virologic response
Compensated cirrhosis 0.57 (0.5–0.7) [19]
Decompensated cirrhosis 0.26 (0.2–0.35) [19]
Hepatocellular carcinoma 0.31 (0.24–0.38) [19]
Liver transplantation 0.7 (0.54–0.76) [19]
Table 4 Base-case results of alternative strategies (for a 30-year-old CHB patient): costs, quality-adjusted life years (QALYs) gained, incremental QALYs,
incremental costs, incremental cost-effectiveness ratios (ICERs), and incidences of cirrhosis, hepatocellular carcinoma and death*
Treatment No treatment Lamivudine Adefovir Telbevudine Entecavir
HBeAg status + - + - + - + - + -
Cumulative costs (¥1000 $) 8.4 8.7 34.2 33.1 51.3 47.0 38.0 36.3 46.6 45.1
Cumulative QALYs 8.8 8.8 10.5 10.9 10.4 11.0 11.0 11.6 11.8 12.7
Incremental QALYs — — 1.7 2.1 1.6 2.2 2.1 2.9 3.1 4.1
Incremental costs (¥1000 $) — — 26.1 24.8 43.5 38.9 30.0 27.9 38.7 36.9
ICER (¥1000 $/QALY) — — 15.6 11.8 27.2 17.4 14.3 9.5 12.6 9.1
Cumulative incidence of cirrhosis (%) 45.6 45.9 35.2 22.8 35.4 31.7 32.5 27.5 23.8 16.8
Cumulative incidence of hepatocellular carcinoma (%) 26.7 26.8 20.8 13.0 21.0 18.9 19.3 16.6 14.8 11.0
Cumulative incidence of death (%) 43.7 44.1 32.7 43.7 33.1 29.3 29.9 25.1 23.0 16.8
*“No treatment” was the baseline strategy compared with other treatment strategies.
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QALY, the majority of simulations featuring treatment with ente-
cavir became cost-effective. Among HBeAg-positive patients, the
percentages of simulations in which entecavir treatment was
cost-effective compared with no treatment, lamivudine, adefovir,
or telbivudine were 92.8%, 97.6%, 100%, and 96.0%, respec-
tively. Among HBeAg-negative patients, the percentages were
98.5%, 99.7%, 100%, and 94.5%, respectively (Fig. 5).
Discussion
The large number of Chinese patients infected with HBV has led
to major health risks and high ﬁnancial burdens, associated
primarily with the subsequent development of cirrhosis and HCC
[22,23]. Lamivudine, adefovir, telbivudine, and entecavir are the
four oral agents currently approved in China for the treatment of
chronic HBV infection. Because these treatment options often
require long-term use (and especially in the case of a developing
country such as China with limited health-care resources), the
costs of these options should be taken into account when formu-
lating recommendations. There are currently several guidelines
regarding the various options for the treatment of CHB, but they
do not consider the cost-effectiveness of these therapies. There-
fore, we performed this economic analysis to identify the most
cost-effective therapeutic strategy.
Our analysis showed three key ﬁndings. First, for both
HBeAg-positive and HBeAg-negative patients, when compared
with the absence of treatment, oral therapeutic treatment could
decrease the risks of complications and mortality (Table 4). Of
the four oral therapeutic strategies examined, entecavir decreased
the cumulative incidences of cirrhosis, HCC, and death by
29.1%, 15.8%, and 27.3%, respectively. These results were
superior to those observed for treatment with lamivudine, ade-
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Figure 2 Results of cost-effectiveness analyses
for the HBeAg-positive (a) and the HBeAg-
negative (b) patients. The vertical axes represent
the lifetime cumulative cost and the horizontal
axes represent the quality-adjusted life years
(QALYs) gained.The“no treatment” strategy is the
least expensive strategy for both cohorts. In both
the HBeAg-positive (a) and the HBeAg-negative
cohorts (b), the entecavir strategy is the dominant
strategy because it is the most effective and the
least expensive of the ﬁve alternative strategies.
Adefovir was less cost-effective than lamivudine,
with fewer health beneﬁts and higher costs, and
lamivudine and telbivudine showed even fewer
health beneﬁts and lower cost-effectiveness.
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fovir, or telbivudine. The results indicate that compared with the
lamivudine, the adefovir, and the telbivudine strategies, an
up-front use of entecavir could achieve the greatest net health
beneﬁts. Second, as indicated in the economic analysis (Fig. 2),
the cost-effectiveness ratio (C/E) of the entecavir strategy was less
than that of the lamivudine, the adefovir, or the telbivudine
approaches. Entecavir was the most cost-effective oral therapeu-
tic approach regardless of HBeAg status. In China, the daily cost
of entecavir was higher than the costs of lamivudine, adefovir, or
telbivudine. The ﬁndings earlier, however, indicate that entecavir
may provide greater health beneﬁts and higher cost-effectiveness
when compared with these other options. The probabilistic sen-
sitivity analysis showed that at a threshold of $20,000, entecavir
would show the highest probability of cost-effectiveness as well
as the greatest number of cost-effective cases (Figs 4 and 5). The
telbivudine strategy was the second most effective option, fol-
lowed by lamivudine. Adefovir was the least effective and com-
pared with the others, the most expensive option. These results
are generally consistent with those of several previous studies
that evaluated the cost-effectiveness of antiviral therapy for CHB.
These studies indicated that entecavir was the preferred option
when compared with lamivudine, adefovir, or telbivudine treat-
ment strategies [2,7,8,24]. Because of the lower utilities and
disease-related costs in Chinese CHB patients [19], however, the
gain in cumulative QALYs and the increased costs observed in
this study were both lower than those reported in previous
studies. The daily cost of telbivudine is similar to the cost of
entecavir in North America and Western Europe [7,8], but it is
about one-half the cost of entecavir in China. This price differ-
ence leads to different results in economic analyses: in North
America and Western Europe, entecavir costs less than telbivu-
dine, whereas in China, the cost of entecavir is higher. If the price
of entecavir was lowered (and on par with the cost of telbivudine
in China), the entecavir strategy would be more cost-effective.
Third, the most inﬂuential parameters that impacted the robust-
ness of the model were the utilities of the CHB and virologic
response health states (Fig. 3). These two health states are fun-
damental conditions throughout the course of the disease, and in
a lifetime analysis, their utilities would signiﬁcantly impact the
QALYs gained. The results obtained in this study differed from
those in previous studies [8,9,25,26]. For instance, the most
inﬂuential parameters found in earlier studies included the prob-
ability of seroconversion with entecavir, the baseline cirrhosis
risk, risk of resistance to lamivudine, etc. The use of different
analytic models and input parameters may have also led to the
differences cited earlier. Our results indicate that improving the
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Figure 3 Tornado graphs of univariate analyses
for the HBeAg-positive (a) and the HBeAg-
negative (b) cohorts. These graphs show the
results of one-way uncertainty analyses of the 10
variables with the most impact on net quality-
adjusted life years (QALYs) gained for 5 alternative
strategies. The width of the bars represents the
range of results when the variables are changed (as
shown in Tables 1–3).The vertical dotted line rep-
resents the base-case results. ADV, adefovir; CC,
compensated cirrhosis; CHB, chronic hepatitis B;
DC, decompensated cirrhosis; ENT, entecavir;
HCC, hepatocellular carcinoma; VR, virologic
response; wtp, willingness to pay.
Cost-Effectiveness of Nucleoside Analog in China 597
quality of life of CHB patients would increase the QALYs gained.
This study has also shown that the quality of life of CHB patients
in China is lower than in other areas. To the best of our knowl-
edge, these differences are attributable to different sociocultural
conditions because a person with CHB in mainland China would
likely confront prejudice and bias in employment, marriage, edu-
cation, etc. Thus, it is important that we eradicate the sociocul-
tural conditions of prejudice. This can be achieved through
increased public health education about hepatitis B and the fos-
tering of awareness around issues of transmission, vaccination,
treatment, and natural history of the disease.
Several limitations of the current analysis must be considered.
First, some of the probability estimates employed were obtained
from literature published abroad and thus do not reﬂect Chinese
data. Second, in the current analyses, because of the absence of
long-term clinical studies, lifetime efﬁcacy and resistance data
were based on the results of clinical trials conducted for much
shorter periods of time (2–5 years). Third, recent studies have
revealed that continuous treatment with oral nucleoside analogs
could delay the clinical progression of patients with advanced
ﬁbrosis or cirrhosis (deﬁned as Ishak ﬁbrosis stages 4–6) [27];
nevertheless, we did not take this issue into account in our
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Figure 4 Cost-effectiveness acceptability curves
showing the probabilities of net beneﬁts achieved
by each strategy for different willingness-to-pay
thresholds (the maximum amount a person would
be willing to pay for a good) in HBeAg-positive (a)
and HBeAg-negative (b) cohorts.The vertical axes
represent the probability of cost-effectiveness.The
horizontal axes represent willingness-to-pay
thresholds to gain one additional quality-adjusted
life year (QALY). For both the HBeAg-positive (a)
and the HBeAg-negative (b) cohorts, the ﬁve
curves represent: the “no treatment” strategy
(dotted line); the lamivudine strategy (dash–dot
line); the adefovir strategy (dashed line); the telbi-
vudine strategy (dash-dot-dot line); and the ente-
cavir strategy (solid line). For example, if the
threshold was set at $20,000 per QALY, the prob-
ability of cost-effectiveness of entecavir was
highest, followed in rank order by the telbivudine,
the “no treatment,” the lamivudine, and the ade-
fovir strategies.
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current model. Fourth, some of the cost parameters for CHB
infection in China were obtained from a study published 5 years
ago. In addition, we did not consider the costs of new laboratory
tests or therapies. Finally, the results obtained from this analysis
apply only to a narrow patient cohort: nucleoside-naïve, HBV
DNA-positive, noncirrhotic, patients with elevated ALT levels,
and without previous interferon therapy. Nonetheless, because
the results of this analysis reﬂect clinical conditions of CHB that
are common in China, we believe that the results can serve as
important reference points for Chinese decision-makers.
In conclusion, our analysis of the clinical and economic out-
comes of the ﬁve competing treatment strategies for the treat-
ment of HBeAg-positive and HBeAg-negative CHB patients
showed that entecavir was the most cost-effective strategy for
China. In addition, because the spread of the virus could be
affected by viral load, we hypothesize that when the replication
of the virus is inhibited by nucleoside analog treatment, the
probability of infection decreases. In CHB patients who receive
antiviral therapy, not only will the disease ameliorate, but the risk
of spreading the disease will also decrease. Furthermore, the
ﬁnancial burden of CHB will decrease simply as a consequence of
a decline in the prevalence of CHB. A recent study conducted by
Xu et al. has shown that lamivudine reduces HBV transmission
from highly viremic mothers to their infants [28]. Another study
in liver transplant patients suggested that the combination of one
nucleoside analog and hepatitis B immunoglobulin (HBIG)
reduced the probability of HBV recurrence [29]. These studies
demonstrate the deterrent effects of nucleoside analogs on the
spread of the HBV virus. Nevertheless, to the best of our knowl-
edge, there are no studies that investigate the effects of nucleoside
analogs on the blood or sexual transmission of the virus. Beyond
the effectiveness of different nucleoside analogs to inhibit the
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Figure 5 Probabilistic results of the incremental cost-effectiveness differences between treatment with entecavir and (a) no treatment, (b) lamivudine, (c) adefovir
and (d) telbivudine for a cohort of 1000 chronic hepatitis B patients.The vertical axes represent the incremental costs.The horizontal axes represent the incremental
quality-adjusted life years (QALYs) gained.The data points below the willingness-to-pay (ceiling ratio) threshold represented by the oblique line reﬂect simulations
in which the cost per QALY gained with entecavir treatment was below the Chinese cost-effectiveness (C/E) threshold of $20,000. For example, the entecavir strategy
would be cost-effective when compared with alternative strategies if a patient treated with entecavir gained 1 incremental QALY and the incremental cost was lower
than $20,000.
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transmission of HBV, it is necessary that we evaluate their eco-
nomic and social value as well; this focus, we believe, will
provide interesting insights into how best to reduce the ﬁnancial
burden associated with the spread of HBV.
Source of ﬁnancial support: This work was supported by the grant from
Ministry of Science and Technology of the People’s Republic of China
(NO.2008ZX09312-007).
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